Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Parkinson's Disease Therapeutics Market The Parkinson's therapeutics market will grow from USD 5.92 Bn in 2024 to USD 12.83 Bn by 2033 at 8 ...

Here are a couple of ASX 200 shares that analysts are tipping to rise strongly from current levels. Here's what you need to ...

ASX companies such as LTR Pharma are finding smarter ways to stretch the value of existing assets and launch into broader ...

As the U.S. stock market navigates a landscape of fluctuating indices and economic indicators, investors are closely monitoring the Federal Reserve's interest rate decisions and major tech earnings ...

Sarepta’s Elevidys is back on the market for ambulatory patients with Duchenne muscular dystrophy, Health Secretary Robert F. Kennedy Jr. reportedly plans to dissolve the U.S. Preventive Services Task ...